$THC

HANEY CECIL D sold (to issuer) $86K of THC

HANEY CECIL D sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · HANEY CECIL D
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure updates insider ownership but does not include any operational, regulatory, or financial developments for Tenet Healthcare.

02

Market read

Traders may briefly reassess sentiment around THC due to insider selling, but the event lacks fundamental catalysts.

03

What to watch

No 10b5-1 plan is cited, but the transaction code D (sale to issuer) can still be non-informational; watch for subsequent insider buys/sales or larger institutional changes.

Relevance 6/10Timing: Filing dated 2026-05-26 for a transaction on 2026-05-22; impact, if any, is most relevant around the filing window.

Background

SEC Form 4 discloses insider transactions; code D indicates sale to the issuer (e.g., buyback participation).

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director Haney Cecil D sold 493 shares to the issuer for about $85.7K at $173.78/share, per SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely small and short-lived unless follow-on filings show broader selling.

Evidence & confidence

Single director transaction size is small versus typical market moves, and the filing provides no new company-specific operating or financial information.

Market effects

No clear read-through to healthcare sector fundamentals from a single director Form 4 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is to the issuer (often tied to buyback/plan mechanics), it may reflect routine liquidity or corporate action rather than bearish expectations.

Key entities

  • Tenet Healthcare Corp

    Company whose director insider transaction was reported on SEC Form 4.

  • Haney Cecil D

    Tenet Healthcare director who sold 493 shares to the issuer on 2026-05-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

$THCMedAI 8/10

Tenet Healthcare at Wells Fargo conference: high-acuity push deepens

Tenet Healthcare (THC) presented at the Wells Fargo Healthcare Conference, outlining a strategy focused on high-acuity care, capital spending, and cost control. The company raised full-year guidance, citing volume growth and cost discipline. Shares are near their 52-week high at $268.82, up over 30% year-to-date. Tenet expects continued pressure in some payer channels and near-term earnings drag from Conifer's transition. Management plans to invest in complex procedures and maintain capital spen